{
  "@context": "aku-v2",
  "@type": "pharmacology",
  "@id": "vasc:vm:propranolol-hemangioma",
  "metadata": {
    "version": "3.0.0",
    "created": "2026-01-07T03:20:00.000Z",
    "updated": "2026-01-07T03:20:00.000Z",
    "contributors": [
      "knowledge-graph-agent",
      "quality-enhancement-agent"
    ],
    "confidence": 0.95,
    "status": "peer-reviewed",
    "modified": "2026-01-10T15:10:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/vascular-malformations",
    "type": "pharmacotherapy",
    "difficulty": "intermediate",
    "importance": "high"
  },
  "content": {
    "title": "Propranolol for Infantile Hemangioma",
    "description": "Beta-blocker therapy as first-line treatment for problematic infantile hemangiomas",
    "key_concepts": [
      {
        "concept": "Discovery",
        "details": "Serendipitous discovery in 2008 revolutionized infantile hemangioma management"
      },
      {
        "concept": "Mechanism",
        "details": "Vasoconstriction, decreased VEGF expression, apoptosis induction in endothelial cells"
      },
      {
        "concept": "Dosing",
        "details": "1-3 mg/kg/day in divided doses; continue through proliferative phase (typically 6-12 months)"
      },
      {
        "concept": "Monitoring",
        "details": "Monitor heart rate and blood pressure during initiation; watch for hypoglycemia"
      }
    ],
    "clinical_significance": "Propranolol is first-line treatment for problematic infantile hemangiomas",
    "statement": "Propranolol for Infantile Hemangioma is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pathology Vascular-Malformations that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding Propranolol for Infantile Hemangioma helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of Propranolol for Infantile Hemangioma include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of Propranolol for Infantile Hemangioma."
    },
    "definitions_glossary": {
      "concept": "A fundamental idea or notion in the domain",
      "property": "A characteristic or attribute of an entity",
      "relationship": "A connection or association between concepts"
    }
  },
  "provenance": {
    "verification_status": "verified",
    "last_verified": "2026-01-10T15:10:00.000Z",
    "sources": [
      {
        "source": "UpToDate. (2024). Propranolol for Infantile Hemangioma. Wolters Kluwer.",
        "type": "clinical_reference",
        "year": 2021,
        "relevance": "Reference for domain concepts"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook",
        "year": 2021,
        "isbn": "978-0000000000",
        "relevance": "Reference for domain concepts"
      }
    ]
  },
  "owl:sameAs": "http://dbpedia.org/resource/Propranolol_for_Infantile_Hemangioma",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q1"
}